---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-087458"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2022-03-29T23:59:59+00:00"
generated_at: "2026-06-26T14:41:00.415749+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dr. Kauffman and Dr. Shacham to depart Karyopharm on May 31, 2022

## Summary
- Dr. Michael Kauffman to depart as Senior Clinical Advisor; receives 18 months salary at $646,875/yr.
- Dr. Sharon Shacham to depart as CSO; receives 18 months salary at $519,901/yr and consulting role.
- Both executives get accelerated vesting of equity awards; options exercisable until March 1, 2025.
- Dr. Shacham receives new grants: 90,000 stock options and 60,000 RSUs under consulting agreement.
- Dr. Kauffman resigned from Board on March 22, 2022; waived nomination rights.

## SEC filing metadata
- accession: 0001193125-22-087458
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2022-03-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/0001193125-22-087458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/d344096d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-087458
- JSON: https://secwatch.observer/filing/0001193125-22-087458.json
- Plain text: https://secwatch.observer/filing/0001193125-22-087458.txt

## Key facts
- Executive change
  Michael G. Kauffman resigned as Senior Clinical Advisor at Karyopharm Therapeutics Inc..
  - Action: resigned
  - Role: Senior Clinical Advisor
  source text: provides for Dr. Kauffman’s separation from employment as Senior Clinical Advisor on May 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/0001193125-22-087458-index.htm
- Executive change
  Sharon Shacham resigned as Chief Scientific Officer at Karyopharm Therapeutics Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: provides for Dr. Shacham’s separation from employment as Chief Scientific Officer on the Separation Date
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312522087458/0001193125-22-087458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.